Gabapentin Prescription for Acute Post-Herpetic Neuralgia: 7-Day Starting Regimen
For a gabapentin-naïve patient with acute post-herpetic neuralgia, prescribe gabapentin 300 mg on Day 1,600 mg/day (300 mg twice daily) on Day 2, and 900 mg/day (300 mg three times daily) on Days 3–7, for a total 7-day supply of 4,500 mg (fifteen 300 mg tablets). 1
FDA-Approved Titration Schedule
The FDA label for postherpetic neuralgia specifies the following initiation protocol 1:
- Day 1: 300 mg once daily
- Day 2: 600 mg/day (300 mg twice daily)
- Day 3 onward: 900 mg/day (300 mg three times daily)
This rapid 3-day titration to 900 mg/day is the foundation dose, with subsequent increases by 300 mg every 3–7 days targeting the therapeutic range of 1800–3600 mg/day 2, 1.
Rationale for This 7-Day Supply
- The minimum effective dose for postherpetic neuralgia is 1800 mg/day (600 mg three times daily), but the FDA-approved titration begins at 900 mg/day by Day 3 to minimize adverse effects 2, 1.
- A 7-day supply allows completion of the initial titration phase (Days 1–3) plus 4 additional days at 900 mg/day, establishing tolerability before the next scheduled dose increase 2.
- Three-times-daily dosing is mandatory because gabapentin has nonlinear, saturable absorption; the interval between doses must not exceed 12 hours 2, 1.
Prescription Details
Gabapentin 300 mg tablets
Dispense: 15 tablets
Directions:
- Day 1: Take one 300 mg tablet at bedtime
- Day 2: Take one 300 mg tablet in the morning and one 300 mg tablet at bedtime
- Days 3–7: Take one 300 mg tablet three times daily (morning, afternoon, bedtime), with no more than 12 hours between doses
Expected Efficacy and Timeline
- Efficacy is demonstrated across the dose range of 1800–3600 mg/day, with 32–38% of patients achieving ≥50% pain reduction versus 17–21% with placebo 2, 3.
- Pain relief develops gradually over several weeks, not immediately; an adequate trial requires 3–8 weeks for titration plus 2 weeks at maximum tolerated dose (approximately 2 months total) 2.
- The additional benefit of doses >1800 mg/day was not consistently demonstrated in clinical trials, though doses up to 3600 mg/day have been well tolerated 1.
Common Adverse Effects at Initial Doses
- Dizziness (20.2%) and somnolence (14.9%) occur most frequently during the initial titration phase (<1800 mg/day) and are typically transient, often subsiding within approximately 10 days 2, 4.
- These side effects do not worsen with dose escalation to ≥1800 mg/day; in fact, rates of dizziness (9.7%) and somnolence (6.9%) at therapeutic doses are comparable to placebo 4.
- Peripheral edema (7.5%) is dose-dependent and increases at doses ≥1800 mg/day 4.
Critical Renal Function Consideration
Before prescribing, calculate creatinine clearance using the Cockcroft-Gault equation, as gabapentin is eliminated primarily by renal excretion and dose reduction is mandatory in renal impairment 2, 1:
| Creatinine Clearance | Total Daily Dose | Dosing Frequency |
|---|---|---|
| ≥60 mL/min | 900–3600 mg | Three times daily |
| 30–59 mL/min | 400–1400 mg | Twice daily |
| 15–29 mL/min | 200–700 mg | Once daily |
| <15 mL/min | 100–300 mg | Once daily |
Elderly patients invariably have reduced renal function, even with normal serum creatinine, due to age-related decline and reduced muscle mass 2, 5.
Follow-Up Plan After 7 Days
- Schedule a follow-up visit at Day 7 to assess tolerability and pain response before increasing to 1200 mg/day (400 mg three times daily) 2.
- Continue titration by 300 mg increments every 3–7 days until reaching the target therapeutic dose of 1800 mg/day (600 mg three times daily), with a maximum of 3600 mg/day if needed 2, 1.
- Allow the full 2-month trial period before declaring treatment failure, as efficacy develops gradually 2.
Common Pitfalls to Avoid
- Never start at high doses (e.g., 800 mg four times daily) without gradual titration, as this dramatically increases the risk of intolerable adverse effects 5.
- Do not use once-daily or twice-daily dosing for standard gabapentin, as three-times-daily administration is essential due to saturable absorption 2.
- Do not abruptly discontinue gabapentin; taper gradually over at least 1 week to avoid withdrawal symptoms 2.
- Do not assume lack of efficacy if adequate time for titration has not been allowed; most patients require several weeks to reach therapeutic doses 2.